Gland Pharma Stock Forecast

Stock Price Forecast

According to 14 analysts polled by S&P Global, Gland Pharma stock has a consensus rating of "Buy" and an average price target of ₹2,190. The average 1-year stock price forecast is 0.43% lower than the current stock price, while the lowest is ₹1,630 (-25.88%) and the highest is ₹2,645 (+20.28%).

Price Target: ₹2,190 (-0.43%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	₹1,630	₹2,190	₹2,280	₹2,645
Change	-25.88%	-0.43%	+3.68%	+20.28%

* Price targets were last updated on May 19, 2026.

Analyst Ratings

The average analyst rating for Gland Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Nov '25	Jan '26	Feb '26	Apr '26	May '26	Jun '26
Strong Buy	3	5	5	5	7	7
Buy	3	3	2	2	3	3
Hold	2	1	1	1	1	1
Sell	1	1	2	2	0	0
Strong Sell	3	3	3	3	3	3
Total	12	13	13	13	14	14

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Alok Dalal Jefferies	Jefferies	Hold Maintains ₹2,080	Hold	Maintains	₹2,080	-5.41%	May 19, 2026
Abdulkader Puranwala ICICI Securities	ICICI Securities	Buy Maintains ₹2,275	Buy	Maintains	₹2,275	+3.46%	Jan 29, 2026
Unknown Analyst Axis Direct No rating	Axis Direct	Buy Maintains ₹2,170	Buy	Maintains	₹2,170	-1.32%	Jan 29, 2026
Unknown Analyst Motilal Oswal No rating	Motilal Oswal	Buy Maintains ₹2,050	Buy	Maintains	₹2,050	-6.78%	Jan 28, 2026

Financial Forecast

Revenue This Year

73.77B

from 64.31B

14.71%

from 64.31B

Revenue Next Year

83.11B

from 73.77B

12.67%

from 73.77B

EPS This Year

74.91

from 63.01

18.88%

from 63.01

EPS Next Year

91.25

from 74.91

21.81%

from 74.91

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026	Mar 31, 2027
Revenue	44.01B	36.25B	56.65B	56.17B	64.31B	73.77B
Revenue Growth	27.08%	-17.64%	56.29%	-0.85%	14.50%	14.71%
Gross Profit	21.51B	17.65B	31.11B	31.54B	39.85B	48.01B
Gross Margin	48.89%	48.70%	54.92%	56.16%	61.97%	65.09%
Operating Income	14.00B	8.84B	9.71B	8.72B	12.06B	14.67B
Net Income	12.12B	7.81B	7.72B	6.99B	10.27B	12.49B
EPS	-	-	-	-	63.01	74.91
EPS Growth	-	-	-	-	48.61%	18.88%
Forward PE	35.96	17.57	29.26	27.55	26.18	29.36
Dividend / Share	-	-	20.00	18.00	20.00	19.55
Dividend Growth	-	-	-	-10.00%	11.11%	-2.25%
Free Cash Flow	493.54M	875.11M	4.10B	5.72B	5.04B	6.68B
No. Analysts	-	-	-	-	-	13

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.

Revenue Forecast

Revenue	2027	2028	2029
High	76.7B
Avg	73.8B
Low	71.4B

Revenue Growth

Revenue Growth	2027	2028	2029
High	19.3%
Avg	14.7%
Low	11.1%

EPS Forecast

EPS	2027	2028	2029
High	-
Avg	74.91
Low	-

EPS Growth

EPS Growth	2027	2028	2029
High	-
Avg	18.9%
Low	-